Patients underwent screening activities, including tumor assessment by computed tomography (CT), prior to study enrollment. On day 1 of cycle 1 (C1D1), patients took a single oral dose of GDC0853 and underwent periodic blood draws over the next 24 h to characterize the acute PK of the drug. Following a 7-day washout, patients began daily oral dosing of GDC0853 on day 8 with assessments as described in METHODS on days 8, 15, 22, 29, and 35. Day 35 of the study represented the end of the DLT window (35 days). Once a patient cleared the DLT window, they continued daily PO dosing with GDC-0853. Blood assessments occurred at the end of every cycle (28 days); tumor size was assessed by CT at the end of every even-numbered cycle through cycle 6, and then every third cycle thereafeter. At the time of study completion/early termination, PK and tumor assessments were repeated.
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